AR079498A1 - Derivados de 2-arilimidazol heteroaromaticos como inhibidores de enzima pde10a - Google Patents
Derivados de 2-arilimidazol heteroaromaticos como inhibidores de enzima pde10aInfo
- Publication number
- AR079498A1 AR079498A1 ARP100104671A ARP100104671A AR079498A1 AR 079498 A1 AR079498 A1 AR 079498A1 AR P100104671 A ARP100104671 A AR P100104671A AR P100104671 A ARP100104671 A AR P100104671A AR 079498 A1 AR079498 A1 AR 079498A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- phenyl
- arylimidazol
- heteroaromatic
- derivatives
- Prior art date
Links
- 108090000790 Enzymes Proteins 0.000 title 1
- 102000004190 Enzymes Human genes 0.000 title 1
- 229940123773 Phosphodiesterase 10A inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- FNZTVMQDZXRQGK-UHFFFAOYSA-N 1h-benzimidazol-2-yl-(5-phenyl-1h-imidazol-2-yl)methanethiol Chemical compound N=1C2=CC=CC=C2NC=1C(S)C(N1)=NC=C1C1=CC=CC=C1 FNZTVMQDZXRQGK-UHFFFAOYSA-N 0.000 abstract 1
- AWDYUWHHJCNRJN-UHFFFAOYSA-N 2-[(5-phenyl-1h-imidazol-2-yl)methylsulfanyl]-1h-benzimidazole Chemical compound N=1C2=CC=CC=C2NC=1SCC(N1)=NC=C1C1=CC=CC=C1 AWDYUWHHJCNRJN-UHFFFAOYSA-N 0.000 abstract 1
- -1 C1-6 alkyl halogen Chemical class 0.000 abstract 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Composiciones farmacéuticas y métodos para tratar enfermedades neurodegenerativas o psiquiatritas- Reivindicacion 1: Un compuesto que tiene la estructura 1 en donde HET-1 es un grupo heteroaromático de la formula 2 que contiene de 2 a 4 átomos de nitrogeno: en donde Y puede ser N o CH, Z puede ser N o C, y en donde HET-1 puede sustituirse opcionalmente con hasta tres sustituyentes R2-R4 individualmente seleccionados de hidrogeno, alquilo C1-6 halogeno; ciano, haloalquilo C1-6; arilo, alcoxi e hidroxialquilo C1-6, y en donde * denota el punto de union, Q es un fenilo, opcionalmente sustituido con uno a cinco sustituyentes, o un grupo heteroaromático de 5 o 6 miembros monocíclico que contiene 1 o 2 heteroátomos. -L- es un enlazante seleccionado de -S-CH2-, -CH2-S-, -CH2-CH2- -CH=CH-, R1 se selecciona de H, alquilo C1-6 alquil C1-6 cicloalquilo C3-8; hidroxialquilo C1-6, CH2CN, CH2C(O)NH2, arilalquilo C1-6, y alquil C1-6- heterocicloalquilo, y tautomeros y sales farmacéuticamente aceptables de los mismos, y formas polimorficas de los mismos, siempre que el compuesto no sea 2-(5-fenil-1H-imidazol-2-ilmetilsulfanil)-1H-benzoimidazol o 2-(5-fenil-1H-imidazol-2-il-sulfanil-metil)-1H-benzoimidazol.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200901341 | 2009-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR079498A1 true AR079498A1 (es) | 2012-02-01 |
Family
ID=44246810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100104671A AR079498A1 (es) | 2009-12-17 | 2010-12-16 | Derivados de 2-arilimidazol heteroaromaticos como inhibidores de enzima pde10a |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US8501797B2 (es) |
| EP (1) | EP2513105B1 (es) |
| JP (1) | JP5698761B2 (es) |
| KR (1) | KR101777889B1 (es) |
| CN (1) | CN102753551B (es) |
| AR (1) | AR079498A1 (es) |
| AU (1) | AU2010333437B2 (es) |
| CA (1) | CA2783727C (es) |
| CO (1) | CO6612246A2 (es) |
| CR (1) | CR20120317A (es) |
| CY (1) | CY1115278T1 (es) |
| DK (1) | DK2513105T3 (es) |
| DO (1) | DOP2012000168A (es) |
| EA (1) | EA021415B1 (es) |
| ES (1) | ES2484692T3 (es) |
| GE (1) | GEP20156242B (es) |
| GT (1) | GT201200180A (es) |
| HR (1) | HRP20140632T1 (es) |
| MA (1) | MA33924B1 (es) |
| MX (1) | MX2012007144A (es) |
| MY (1) | MY158202A (es) |
| NZ (1) | NZ600416A (es) |
| PH (1) | PH12012501223A1 (es) |
| PL (1) | PL2513105T3 (es) |
| PT (1) | PT2513105E (es) |
| RS (1) | RS53413B (es) |
| SG (1) | SG181536A1 (es) |
| SI (1) | SI2513105T1 (es) |
| SM (1) | SMT201400114B (es) |
| TN (1) | TN2012000287A1 (es) |
| TW (1) | TWI481607B (es) |
| UA (1) | UA107817C2 (es) |
| WO (1) | WO2011072696A1 (es) |
| ZA (1) | ZA201204418B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI487705B (zh) | 2009-12-17 | 2015-06-11 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物 |
| TWI485151B (zh) | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物 |
| TWI481607B (zh) | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 |
| JO3089B1 (ar) * | 2010-11-19 | 2017-03-15 | H Lundbeck As | مشتقات ايميدازول كمثبطات لانزيمات pde10a |
| CA2822071C (en) | 2010-12-17 | 2019-07-16 | Reata Pharmaceuticals, Inc. | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators |
| RU2746159C2 (ru) | 2010-12-17 | 2021-04-08 | Новартис Аг | Кристаллические формы 5-хлор-n2-(2-изопропокси-5-метил-4-пиперидин-4-ил-фенил)-n4-[2-(пропан-2-сульфонил)-фенил]-пиримидин-2,4-диамина |
| WO2012096929A2 (en) | 2011-01-11 | 2012-07-19 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| US8772316B2 (en) | 2011-02-18 | 2014-07-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE10A) |
| US9938269B2 (en) * | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| CA2845578C (en) * | 2011-08-25 | 2016-02-16 | Merck Sharp & Dohme Corp. | Pyrimidine pde10 inhibitors |
| TWI570124B (zh) | 2011-12-21 | 2017-02-11 | Ｈ 朗德貝克公司 | 作為ｐｄｅ１０ａ酵素抑制劑的喹啉衍生物 |
| WO2013107856A1 (en) * | 2012-01-20 | 2013-07-25 | H. Lundbeck A/S | Imidazole derivatives as pde10a enzyme inhibitors |
| WO2013127817A1 (en) | 2012-02-27 | 2013-09-06 | H. Lundbeck A/S | Imidazole derivatives as pde10a enzyme inhibitors |
| US9505751B2 (en) * | 2012-06-19 | 2016-11-29 | Sunovion Pharmaceuticals Inc. | Substituted [1,2,4]triazolo[1,5-a]pyrazines as phosphodiesterase inhibitors |
| WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
| AU2017353310B2 (en) * | 2016-11-02 | 2021-08-12 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as PDE2 inhibitors |
| GB202002926D0 (en) * | 2020-02-28 | 2020-04-15 | Benevolentai Tech Limited | Compositions and uses thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8307865D0 (en) | 1983-03-22 | 1983-04-27 | Fujisawa Pharmaceutical Co | Benzimidazole derivatives |
| US5571775A (en) | 1994-07-11 | 1996-11-05 | Dowelanco | N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides |
| US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| IL149106A0 (en) | 2001-04-20 | 2002-11-10 | Pfizer Prod Inc | Therapeutic use of selective pde10 inhibitors |
| FR2824065A1 (fr) | 2001-04-26 | 2002-10-31 | Neuro3D | Composes inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations |
| CA2494987C (en) * | 2002-08-09 | 2012-04-17 | Astrazeneca Ab | Isoxazoles and their use as modulators of metabotropic glutamate receptor-5 |
| DE60324449D1 (de) | 2002-10-30 | 2008-12-11 | Via Pharmaceuticals Inc | Inhibitoren der phosphodiesterase der zyklischen n, und deren verwendung in therapie |
| WO2005003129A1 (en) | 2003-06-30 | 2005-01-13 | Altana Pharma Ag | Pyrrolodihydroisoquinolines as pde10 inhibitors |
| WO2005002579A1 (en) | 2003-06-30 | 2005-01-13 | Altana Pharma Ag | Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors |
| EP1651251A4 (en) | 2003-07-31 | 2008-06-18 | Bayer Pharmaceuticals Corp | METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS |
| WO2005014588A1 (en) | 2003-08-01 | 2005-02-17 | Argenta Discovery Limited | Substituted thienyl-hydroxamic acids having histone deacetylase activity |
| EP1723134A2 (en) | 2004-02-18 | 2006-11-22 | Pfizer Products Incorporated | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline |
| FR2870539B1 (fr) | 2004-05-19 | 2006-08-04 | Greenpharma Sa Sa | Nouvelles methodes et medicaments |
| MXPA06014236A (es) | 2004-06-07 | 2007-02-14 | Pfizer Prod Inc | Inhibicion de la fosfodiesterasa 10 como tratamiento para las afecciones relacionadas con el sindrome metabolico y con la obesidad. |
| US20060019975A1 (en) | 2004-07-23 | 2006-01-26 | Pfizer Inc | Novel piperidyl derivatives of quinazoline and isoquinoline |
| CA2578996A1 (en) | 2004-09-03 | 2006-03-16 | Memory Pharmaceuticals Corporation | 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
| US20090176829A1 (en) * | 2006-05-02 | 2009-07-09 | Pfizer Inc | Bicyclic heteroaryl compounds as pde10 inhibitors |
| US20080090834A1 (en) * | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| US8492394B2 (en) * | 2006-07-10 | 2013-07-23 | H. Lundbeck A/S | (3-aryl-piperazin-1-yl), (2-aryl-morpholin-4-yl) and (2-aryl-thiomorpholin-4-yl) derivatives of 6,7-dialkoxy-quinazoline, 6,7-dialkoxyphtalazine and 6,7-dialkoxyisoquinoline as PDE10A enzyme inhibitors |
| JP2010533715A (ja) | 2007-07-17 | 2010-10-28 | アムジエン・インコーポレーテツド | 複素環系ｐｋｂ調節剤 |
| TWI501965B (zh) * | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
| TWI487705B (zh) * | 2009-12-17 | 2015-06-11 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物 |
| TWI481607B (zh) | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 |
| TWI485151B (zh) * | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物 |
-
2010
- 2010-12-14 TW TW099143693A patent/TWI481607B/zh not_active IP Right Cessation
- 2010-12-15 SG SG2012041547A patent/SG181536A1/en unknown
- 2010-12-15 US US13/515,325 patent/US8501797B2/en not_active Expired - Fee Related
- 2010-12-15 EA EA201290518A patent/EA021415B1/ru not_active IP Right Cessation
- 2010-12-15 CA CA2783727A patent/CA2783727C/en not_active Expired - Fee Related
- 2010-12-15 PL PL10797990T patent/PL2513105T3/pl unknown
- 2010-12-15 PT PT107979908T patent/PT2513105E/pt unknown
- 2010-12-15 DK DK10797990.8T patent/DK2513105T3/da active
- 2010-12-15 AU AU2010333437A patent/AU2010333437B2/en not_active Ceased
- 2010-12-15 JP JP2012543476A patent/JP5698761B2/ja not_active Expired - Fee Related
- 2010-12-15 KR KR1020127015565A patent/KR101777889B1/ko not_active Expired - Fee Related
- 2010-12-15 MX MX2012007144A patent/MX2012007144A/es active IP Right Grant
- 2010-12-15 HR HRP20140632AT patent/HRP20140632T1/hr unknown
- 2010-12-15 MA MA35065A patent/MA33924B1/fr unknown
- 2010-12-15 SI SI201030671T patent/SI2513105T1/sl unknown
- 2010-12-15 MY MYPI2012002597A patent/MY158202A/en unknown
- 2010-12-15 CN CN201080064084.5A patent/CN102753551B/zh not_active Expired - Fee Related
- 2010-12-15 RS RS20140371A patent/RS53413B/sr unknown
- 2010-12-15 ES ES10797990.8T patent/ES2484692T3/es active Active
- 2010-12-15 PH PH1/2012/501223A patent/PH12012501223A1/en unknown
- 2010-12-15 WO PCT/DK2010/050343 patent/WO2011072696A1/en not_active Ceased
- 2010-12-15 GE GEAP201012787A patent/GEP20156242B/en unknown
- 2010-12-15 EP EP10797990.8A patent/EP2513105B1/en active Active
- 2010-12-15 UA UAA201207978A patent/UA107817C2/uk unknown
- 2010-12-15 NZ NZ600416A patent/NZ600416A/xx not_active IP Right Cessation
- 2010-12-16 AR ARP100104671A patent/AR079498A1/es unknown
-
2012
- 2012-06-05 TN TNP2012000287A patent/TN2012000287A1/en unknown
- 2012-06-07 GT GT201200180A patent/GT201200180A/es unknown
- 2012-06-12 CR CR20120317A patent/CR20120317A/es unknown
- 2012-06-15 CO CO12101119A patent/CO6612246A2/es active IP Right Grant
- 2012-06-15 ZA ZA2012/04418A patent/ZA201204418B/en unknown
- 2012-06-15 DO DO2012000168A patent/DOP2012000168A/es unknown
-
2013
- 2013-06-24 US US13/924,712 patent/US8927738B2/en not_active Expired - Fee Related
-
2014
- 2014-07-18 CY CY20141100539T patent/CY1115278T1/el unknown
- 2014-08-18 SM SM201400114T patent/SMT201400114B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR079498A1 (es) | Derivados de 2-arilimidazol heteroaromaticos como inhibidores de enzima pde10a | |
| AR072199A1 (es) | Derivados de fenilimidazol como inhibidores de la enzima pde10a | |
| AR079497A1 (es) | Derivados fenilimidazol que comprenden un enlazante de etinileno como inhibidores de enzima pde10a | |
| AR079495A1 (es) | Derivados de fenilimidazol heteroaromaticos como inhibidores de enzima pde10a | |
| AR079496A1 (es) | Derivados de aril triazol heteroaromaticos como inhibidores de enzima pde10a | |
| ES2524966T3 (es) | Derivados de tieno[3,2-c]piridina como inhibidores de quinasas para uso en el tratamiento del cáncer | |
| AR083926A1 (es) | Derivados de imidazol como inhibidores de la enzima pde10a | |
| ES2600636T3 (es) | Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2 | |
| AR072166A1 (es) | Derivado de piperidina y su uso como inhibidor de renina superior | |
| ES2521596T3 (es) | Combinación del compuesto GlyT1 con antipsicóticos | |
| CR20120053A (es) | Compuestos y metodos inhibidores de jak de pirazolopirimidina | |
| ES2590504T3 (es) | N-ciclilamidas como nematicidas | |
| AR067946A1 (es) | Imidazoles biciclicos fusionados | |
| AR073136A1 (es) | Compuestos de pirrol | |
| ES2570756T3 (es) | Derivados pirimidinilpirrolopiridinona sustituidos, proceso para su preparación y su uso como inhibidores de cinasa | |
| PE20140192A1 (es) | Derivados de bencimidazol como inhibidores de cinasa pi3 | |
| PE20090992A1 (es) | Derivados de fenil-amino-pirimidina como agentes inhibidores de cinasa | |
| PE20130382A1 (es) | Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a | |
| PE20121509A1 (es) | Compuestos de triazolopiridinas como inhibidores de quinasa mps-1 | |
| CO6210721A2 (es) | Acilaminopirazoles como inhibidores de fgfr | |
| AR080314A1 (es) | Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa | |
| ES2669189T3 (es) | Compuestos de carbazol útiles como inhibidores del bromodominio | |
| CO6231028A2 (es) | Compuestos y composiciones como inhibidores de la proteina quinasa | |
| CO6220935A2 (es) | Derivados de 1,2,4-triazol como moduladores de mglur5 | |
| PE20091243A1 (es) | Compuesto heterociclico fusionado |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |